Conference Proceedings
PEMBROLIZUMAB PLUS LENVATINIB VS CHEMOTHERAPY AND LENVATINIB MONOTHERAPY FOR RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA THAT PROGRESSED ON PLATINUM THERAPY AND IMMUNOTHERAPY: LEAP-009
Kevin Harrington, Ezra Cohen, Lilian Siu, Danny Rischin, Lisa Licitra, Jan Vermorken, Le Quynh-Thu, Makoto Tahara, Jean-Pascal Machiels, Natalyn Hawk, Joy Ge, Behzad Bidadi, Ramona Swaby, Barbara Burtness
JOURNAL FOR IMMUNOTHERAPY OF CANCER | BMJ PUBLISHING GROUP | Published : 2020
Abstract
Pembrolizumab alone and in combination with platinum-based chemotherapy have become standard first-line treatment options for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), and there is a growing unmet need for safe and efficacious treatment options for R/M HNSCC that has progressed on or after platinum-based chemotherapy and immunotherapy. Data from Study 111/KEYNOTE-146 showed promising antitumor activity and acceptable safety for the PD-1 inhibitor pembrolizumab given in combination with the multikinase inhibitor lenvatinib in patients with metastatic HNSCC.1 LEAP-009 (NCT04428151), a global, randomized, open-label, phase 2 trial, will assess the efficacy and safe..
View full abstract